Ascendis Pharma A/S ASND
225.60
(5.10)
(2.21%)
as of 25 Sep
- Market cap
- $15.7B
- P/E
- 16.3×
Follow ASND
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
19.23 | 24.33 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
14.16 | 14.15 | 15.86 | 16.72 | |
P/FCF ratio |
44.29 | 287.13 | 251.54 | 0.00 | |
P/Operating CF |
52.39 | (1,561.25) | 154.27 | 6,759.70 | |
P/B ratio |
10.28 | 24.70 | 0.00 | 0.00 | |
Price to Tangible BV |
10.30 | 24.89 | 0.00 | 0.00 | |
EV/Sales |
13.81 | 14.53 | 16.22 | 17.16 | |
EV/EBITDA |
52.11 | 3,004.22 | 0.00 | 0.00 | |
EV/Operating CF |
41.43 | 216.16 | 216.68 | (109.45) | |
EV/FCF |
43.20 | 294.85 | 257.17 | (103.62) | |
Quick Ratio |
2.23 | 0.68 | 0.72 | 0.70 | |
Current Ratio |
2.99 | 1.00 | 1.04 | 1.03 | |
Net Debt/EBITDA |
(1.61) | 11.15 | 36.90 | 17.98 | |
Debt/Assets |
19.69% | 44.76% | 66.93% | 70.46% | |
Debt/Equity |
0.31 | 1.84 | (5.35) | (4.67) | |
Asset Turnover |
0.62 | 0.58 | 0.59 | 0.57 | |
Operating CF/Net income |
1.36 | (0.01) | (1.95) | (0.03) | |
Capex/Depreciation |
(0.70) | (1.83) | (0.73) | (0.05) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
22.37% | 23.94% | 33.08% | 31.31% | |
Selling, General and Administrative Expense of Revenue |
51.09% | 58.89% | 56.19% | 53.08% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.67% | 12.31% | 10.98% | 15.09% | |
Graham Net Nets |
0.04 | (0.03) | (0.03) | (0.03) | |
Graham Number |
90.00 | 44.25 | 16.95 | 17.87 | |
Earnings Yield |
5.20% | 4.11% | (1.97%) | (2.13%) | |
Free Cash Flow Yield |
2.26% | 0.35% | 0.40% | (0.99%) | |
Revenue per Share |
6.13 | 4.68 | 4.61 | 4.11 | |
Operating CF per Share |
5.09 | (0.15) | 1.38 | 0.03 | |
Capex per Share |
(0.06) | (0.15) | (0.06) | 0.00 | |
Free Cash Flow per Share |
5.03 | (0.29) | 1.32 | 0.03 | |
Cash per Share |
14.68 | 10.87 | 11.50 | 10.37 | |
Shareholders Equity per Share |
25.96 | 9.26 | (3.04) | (3.35) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
25.96 | 9.26 | (3.04) | (3.35) | |
Free Cash Flow |
323.87 | (18.06) | 80.13 | 1.56 | |
Working Capital |
1,076.11 | (5.18) | 44.80 | 36.58 | |
Capital Expenditures |
(3.70) | (9.03) | (3.65) | (0.23) | |
Net Current Asset Value |
628.88 | (459.93) | (403.24) | (363.58) | |
EV/EBIT |
55.60 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.03 | 0.01 | 0.00 | |
Net Profit Margin |
61.00% | 255.21% | (15.37%) | (28.55%) | |
Price to Operating Income |
57.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
199.09 | 155.52 | 185.21 | 113.74 | |
Average Payables |
113.61 | 90.43 | 103.44 | 87.32 | |
Average Inventory |
352.75 | 338.33 | 330.52 | 322.45 | |
Average Assets |
1,946.47 | 1,731.43 | 1,375.03 | 1,276.26 | |
Average Common Equity |
728.64 | 185.58 | (149.30) | (155.24) |
Columns are period end dates